This site is intended for U.S. healthcare professionals.

Visit Pfizer MedicalVisit Pfizer MedicalLoading

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

About HYMPAVZIAbout
HYMPAVZIOverviewHYMPAVZI in ActionEfficacyEfficacyStudy DesignPrimary EndpointsSecondary EndpointsSafetyDosing & AdminDosing 

& AdminDosingPen OverviewInjection OverviewPatient ProfilesPatient
ProfilesIdentifying PatientsUnmet NeedsResourcesResourcesResourcesPatient Savings & Support
Full Prescribing InformationPatient InformationInstructions for UseIndication Patient Site
Understanding ongoing patient needs in hemophiliaUnderstanding ongoing patient needs in hemophilia

Despite advances in hemophilia treatment, unmet needs remain beyond bleed protection.1-3

Despite advances in hemophilia treatment, unmet needs remain beyond bleed protection.1-3

 Stress related to factor infusion
  • 43% of patients find it stressful to have to infuse factor regularly4
Administration complications
  • 33% of patients consider storing, preparing, and mixing FVIII treatment disruptive to their daily routine5
  • 37% of patients who infuse factor concentrate experience challenges with required venous access6
 Travel concerns
  • 71% of patients worry about taking longer trips5
  • 60% of patients report that storage requirements restrict their ability to travel by airplane5
 Storage restrictions
  • Prophylaxis storage temperature can have a significant impact on patients’ treatment preference. In one survey, almost half of participants (47%) reported discarding unused product. This was due to storage issues in 27% of cases7
 Factor inhibitor development
  • Patients with hemophilia may develop inhibitors to factor, which affect around 30% of people with hemophilia A and 3% of people with hemophilia B. These patients also have a higher rate of severe bleeds, hospitalization, treatment costs, and mortality8,9

Stress related to factor infusion

43% of patients find it stressful to have to infuse factor regularly4 Administration complications
  • 33% of patients consider storing, preparing, and mixing FVIII treatment disruptive to their daily routine5
  • 37% of patients who infuse factor concentrate experience challenges with required venous access6

Travel concerns

  • 71% of patients worry about taking longer trips5
  • 60% of patients report that storage requirements restrict their ability to travel by airplane5

Storage restrictions

  • Prophylaxis storage temperature can have a significant impact on patients’ treatment preference. In one survey, almost half of participants (47%) reported discarding unused product. This was due to storage issues in 27% of cases7

Factor inhibitor development

  • Patients with hemophilia may develop inhibitors to factor, which affect around 30% of people with hemophilia A and 3% of people with hemophilia B. These patients also have a higher rate of severe bleeds, hospitalization, treatment costs, and mortality8,9
 Resources and support

Download educational resources that can support you and your patients

 See the resources LoadingReferences:1. Ozelo MC, et al. 2022;6(3):e12695. 2. Thornburg CD, et al. Patient Prefer Adherence. 2017;11:1677-1686. 3. Brod M, et al. J Patient Rep Outcomes. 2023;7(1):17. 4. Steen Carlsson K, et al. 2017;23(6):894-903. 5. Tischer B, et al. Patient Prefer Adherence. 2018;12:431-441. 6. Guillon P, et al. Haemophilia. 2015;21(1):21-26. 7. Napolitano M, et al. Drugs R D. 2019;19(4):381-390. 8. Meeks SL, et al. Hematology Am Soc Hematol Educ Program. 2016;2016(1):657-662. 9. Soucie JM, et al. Am J Prev Med. 2014;47(5):669-673.Patient ProfilesPatient Profiles Resources and support

Download educational resources that can support you and your patients

See the resources
Loading

HYMPAVZI is a trademark of Pfizer Inc.

HYMPAVZI is a trademark of Pfizer Inc.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-HYM-USA-0073
Indications and usageHYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
 
  • hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or
  • hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.
Helix ISI Modal Headline Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Important Safety InformationHYMPAVZI is a tissue factor pathway inhibitor (TFPI) antagonist and may increase the risk of thromboembolic complications. Interrupt HYMPAVZI prophylaxis if diagnostic findings consistent with thromboembolism occur and manage as clinically indicated. If factor VIII or factor IX products are indicated in a patient receiving HYMPAVZI prophylaxis, the minimum effective dose of factor VIII or factor IX according to the product label is recommended.

HYMPAVZI may cause hypersensitivity reactions (including, but not limited to, urticaria and pruritus). If HYMPAVZI-treated patients develop a severe hypersensitivity reaction, advise patients to discontinue HYMPAVZI and seek immediate emergency treatment.

Based on its mechanism of action, HYMPAVZI may cause fetal harm when administered to a pregnant woman. Verify that females of reproductive potential are not pregnant prior to initiating HYMPAVZI. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with HYMPAVZI and for 2 months after the last dose.

A serious adverse reaction of peripheral swelling occurred in one patient. Adverse reactions reported in ≥3% of patients treated with HYMPAVZI in clinical trials included injection site reaction (9% of patients); headache (7% of patients); pruritus (3% of patients).IndicationHYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
  • hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or
  • hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.